2016
DOI: 10.21873/anticanres.11010
|View full text |Cite
|
Sign up to set email alerts
|

Mutation Screening of Her-2, N-ras and Nf1 Genes in Brain Tumor Biopsies

Abstract: Activated N-ras appears to be a major oncogene in brain oncogenesis, exhibiting the most important role in the her-2/N-ras/nf1 pathway.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
6
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 24 publications
1
6
0
Order By: Relevance
“…2 ). Although this result is somewhat at the upper limit, it is consistent with similarly structured studies in other countries reporting HPV prevalence ranging from 35.3% to 88.9% in women with cytologic abnormalities ( 4 , 12 19 ).…”
Section: Discussionsupporting
confidence: 91%
“…2 ). Although this result is somewhat at the upper limit, it is consistent with similarly structured studies in other countries reporting HPV prevalence ranging from 35.3% to 88.9% in women with cytologic abnormalities ( 4 , 12 19 ).…”
Section: Discussionsupporting
confidence: 91%
“…The only result from StringDB based graphs for possible protein complexes within glioblastoma multiforme listed HER2 and several RAS proto-oncogenes. HER2 gene amplification has been shown in glioblastoma multiforme in correlation to KRAS and NRAS mutations [79,80].…”
Section: Discussionmentioning
confidence: 99%
“…The recent success of new formulations developed in ADCs to treat other solid tumors such as transtuzumab emtansine (T-DM1) for HER2-positive in breast cancer patients has been very encouraging even in brain metastasis [19, 20]. T-DM1 has gained recently attention as a possible therapy to treat glioblastoma because its capacity to pass blood brain barrier (BBB) from patients with brain metastasis and because HER-2 is also expressed in some glioblastomas [21, 22]. Another ADC's with recent success in the treatment of other malignancies are brentuximab vedotin (BV) (an antibody–drug conjugate targeting CD30) and inotuzumab ozogamicin (a humanized CD22 monoclonal antibody linked to the cytotoxic agent calicheamicin) used in Hodgkin lymphoma [23] and the treatment of B cell malignancies [24], respectively.…”
Section: Discussionmentioning
confidence: 99%